/
/
Clinical Trial: Phase 1 BCMA-CD3 Bispecific Antibody for Relapsed/Refractory Myeloma Patients
Clinical Trial: Phase 1 BCMA-CD3 Bispecific Antibody for Relapsed/Refractory Myeloma Patients image
Clinical Trial: Phase 1 BCMA-CD3 Bispecific Antibody for Relapsed/Refractory Myeloma Patients
Posted Jun 23, 2018

A new Phase 1 study is open to test different doses of a new bispecific antibody treatment for patients with relapsed/refractory multiple myeloma.

The new drug (called PF-06863135) is a bispecific antibody, which is a new treatment designed to have two different targets. In this case, PF-06863135 targets CD3, which is found on T Cells, and BCMA, which may be expressed by myeloma cells. PF-06863135 draws them together, which allows the T cell to better target and potentially kill the myeloma cell.

This trial is seeking an estimated 80 patients, and will be testing dose escalation, followed by dose expansion to assess overall response and duration of response. This trial is currently open and accepting patients at multiple locations in the US.

Patients must have relapsed/refractory multiple myeloma, and adequate bone marrow, kidney and liver function.

Click the link below to learn more about this study and see if you are eligible. You can also call SparkCures with any questions at (888) 828-2206.

To learn more, find this study on SparkCures here:

Phase 1 BCMA-CD3 Bispecific Antibody Trial

You can learn more about bispecific antibodies in a prior Myeloma Crowd article here

 

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.

More Life with Myeloma Articles

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Genentech
Abbvie
Bristol Myers Squibb
Janssen Oncology
GSK

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / Myeloma Crowd is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

 https://www.guidestar.org/profile/45-5354811